Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

Manhattan BioSolutions Announces Grant Award from the New Jersey CSIT

Fort Lee, New Jersey Mar 10, 2022 (Issuewire.com) – Manhattan BioSolutions, an emerging biotechnology company focused on the development of innovative biologic therapies for […]

Published December 19, 2023

Manhattan BioSolutions Named as an Awardee of Science in the City QuickFire Challenge

Published May 22, 2023

Manhattan BioSolutions, Inc. Selected to be Featured in New York Pavilion at BIO International Convention

https://www.issuewire.com/manhattan-biosolutions-inc-selected-to-be-featured-in-new-york-pavilion-at-bio-international-convention-1766550010501619 New York City, New York May 22, 2023 (Issuewire.com) – Manhattan BioSolutions, Inc. (“Manhattan Bio”), an emerging biotechnology company developing new classes of […]

Published September 1, 2018

Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball= Project Number: 1R43CA228746-01A1 Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER

Back to post list
Next post Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University